Abstract: A perfume composition comprising an effective amount of at least one alkadienenitrile selected from 4,8-undecadienenitrile and isomers thereof, 4,9-dodecadienenitrile and isomers thereof, and 4,10-tridecadienenitrile and isomers thereof. The isomers of 4,8-undecadienenitrile comprise Z,Z-4,8-undecadienenitrile, E,E-4,8-undecadienenitrile, and mixed Z/E isomers of 4,8-undecadienenitrile; the isomers of 4,9-dodecadienenitrile comprise Z,Z-4,9-dodecadienenitrile, E,E-4,9-dodecadienenitrile, and mixed Z/E isomers of 4,9-dodecadienenitrile; and the isomers of 4,10-tridecadienenitrile comprise Z,Z-4,10-tridecadienenitrile, E,E-4,10-tridecadienenitrile, and mixed Z/E isomers of 4,10-tridecadienenitrile. A composition comprising an effective amount of at least one alkadienenitrile selected from 4,8-undecadienenitrile and isomers thereof, 4,9-dodecadienenitrile and isomers thereof, and 4,10-tridecadienenitrile and isomers thereof. Processes for the preparation of the isomeric alkadienenitriles are provided.

Abstract: A perfume composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. The isomers of 4,8-undecadienal comprise Z,Z-4,8-undecadienal, E,E-4,8-undecadienal, and mixed Z/E isomers of 4,8-undecadienal; the isomers of 4,9-dodecadienal comprise Z,Z-4,9-dodecadienal, E,E-4,9-dodecadienal, and mixed Z/E isomers of 4,9-dodecadienal; and the isomers of 4,10-tridecadienal comprise Z,Z-4,10-tridecadienal, E,E-4,10-tridecadienal, and mixed Z/E isomers of 4,10-tridecadienal. A composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. Processes for the preparation of the isomer mixtures of alkadienals are provided.

Abstract: A perfume composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. The isomers of 4,8-undecadienal comprise Z,Z-4,8-undecadienal, E,E-4,8-undecadienal, and mixed Z/E isomers of 4,8-undecadienal; the isomers of 4,9-dodecadienal comprise Z,Z-4,9-dodecadienal, E,E-4,9-dodecadienal, and mixed Z/E isomers of 4,9-dodecadienal; and the isomers of 4,10-tridecadienal comprise Z,Z-4,10-tridecadienal, E,E-4,10-tridecadienal, and mixed Z/E isomers of 4,10-tridecadienal. A composition comprising an effective amount of at least one alkadienal selected from 4,8-undecadienal and isomers thereof, 4,9-dodecadienal and isomers thereof, and 4,10-tridecadienal and isomers thereof. Processes for the preparation of the isomer mixtures of alkadienals are provided.

Abstract: The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—useful in the treatment of cancer and hyperproliferative diseases.

Abstract: The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

Abstract: Quinoline derivatives, particularly 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid; 3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine; N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide; and N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Abstract: Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with DNMT3b activity. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Abstract: Compounds of the general formula wherein R is selected from the group consisting essentially of hydrogen, methyl, ethyl, phenyl, a carboxyl, or naphthyl substituted or a carbonyl substituted, alkyl of from 3 to 20 carbon atoms, a mono, bi or tri cyclic aryl or substituted aryl for the inhibition of phosphatase enzymes, including metallophosphatases; and, novel methods for synthesizing such compounds. The methods of use include the administration of an effective amount of the compound to provide effective phosphatase inhibition and therapeutic use to treat or prevent certain diseases, which utilize specific phosphatase enzymes.

Abstract: Novel compounds act as molecular inhibitors to target new enzymatic targets on bacteria and provide a new class of bactericidal compounds. The compounds provide for selective inhibition of Type I methionyl aminopeptidases (MetAPs) in bacteria. Because humans and other animals have both type-I and type-II MetAPs, which are functionally equivalent, the compounds are bactericidal but do not completely inhibit MetAP activity in humans and other animals. The compounds also have anti-microbial activity in microbes other than bacteria provided the targeted microbes have predominately type-I MetAP.